Last reviewed · How we verify
NCT07461181
A Study to Evaluate the Safety, Tolerability, PK, PD, and Preliminary Efficacy of CS01 in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1, PHASE2 trial testing CS01 (an anti-OX40 antibody) in Locally Advanced or Metastatic Solid Tumors in 10 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2026
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 30 December 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CS01 (an anti-OX40 antibody) — full drug profile →
Conditions studied
- Locally Advanced or Metastatic Solid Tumors — all drugs for Locally Advanced or Metastatic Solid Tumors →
Sponsor
Ruijin Hospital
Who can join
18 and older, any sex, with Locally Advanced or Metastatic Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an investigator-initiated clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CS01 in patients with locally advanced or metastatic solid tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07461181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced or Metastatic Solid Tumors
Currently open trials in the same condition.
- NCT07202364 — A Study of YL202 in Patients With Advanced Solid Tumors · Phase 2 · recruiting
- NCT06418061 — Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
- NCT06545331 — Study of XB010 in Subjects With Solid Tumors · Phase 1 · recruiting
- NCT06328439 — A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT06244992 — PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07461181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 10 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07461181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing